FDA's Quality Management Maturity Program – Why should CDMOs adhere to the new CDER's Rati

webinar

Development Drug Product General

As a Contract Development and Manufacturing Organization (CDMO), our primary goal is to produce high-quality pharmaceuticals that meet the needs of clients and ensure the safety and well-being of the final consumers – patients. To achieve this, it is essential to have an in-depth understanding of the FDA’s Quality Management Maturity (QMM) program. The objective of this webinar is to explore the QMM program and its benefits, including the rating system currently being developed by the FDA’s Center for Drug Evaluation and Research (CDER) to incentivize drug manufacturers to achieve QMM. We will also explore the possible challenges that CDMOs will face in achieving high scores and the steps to overcome these challenges, to ensure they deliver high-quality products.

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

More from Curia

publications patents

Poster: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody

We have identified a dual antiLILRB2/LILRB4 antagonist. Targeting MDSCs with this antibody offers great promise for immunotherapy for cancer as well as its immense potential for synergy with PD-1 blockade.

article

Trends and Challenges in the Pharmaceutical Industry

Significant changes have taken place in the life sciences industry over the past few years. Since the Covid-19 pandemic, the U.S. government has urged biotech and pharmaceutical companies to increase domestic production in order to secure the drug su...